“The Promise of Incretin-Based Pharmacotherapies for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)” explores emerging therapeutic strategies targeting the incretin axis. This article highlights the evolving role of GLP-1 receptor agonists and related agents in addressing the complex metabolic and hepatic landscape of MAFLD.

A must-read for clinicians and researchers advancing the frontiers of hepatometabolic care.